Evidence map›Paper›PMID 41957532›Full record

ArticleChemMedChem2026

Structure- and Ligand-Based Discovery of Novel 3-Chymotrypsin-Like Protease Nonpeptidomimetic Hits.

Sabrina Silva-Mendonça, Donald Seanego, Christopher Jurisch, Melina Mottin, Flávia Nader Motta, Beatriz S A Rodrigues, Gilberto S M Junior, Alexandra Maria Dos Santos Carvalho, Fábio Muniz de Oliveira, Sunniva Sigurdardóttir and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sabrina Silva-MendonçaLaboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil.ORCID https://orcid.org/0000-0002-7040-0865
Donald SeanegoHolistic Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch, South Africa.ORCID https://orcid.org/0000-0001-8871-5251
Christopher JurischHolistic Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch, South Africa.ORCID https://orcid.org/0000-0001-5032-9363
Melina MottinLaboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil.ORCID https://orcid.org/0000-0003-0878-9029
Flávia Nader MottaLaboratory of Pathogen-Host Interaction (LIPH), Institute of Biological Sciences, Universidade de Brasília, Brasília, Brazil.
Beatriz S A RodriguesLaboratory of Pathogen-Host Interaction (LIPH), Institute of Biological Sciences, Universidade de Brasília, Brasília, Brazil.
Gilberto S M JuniorLaboratory of Pathogen-Host Interaction (LIPH), Institute of Biological Sciences, Universidade de Brasília, Brasília, Brazil.
Alexandra Maria Dos Santos CarvalhoLaboratory of Pathogen-Host Interaction (LIPH), Institute of Biological Sciences, Universidade de Brasília, Brasília, Brazil.ORCID https://orcid.org/0000-0002-3317-9479
Fábio Muniz de OliveiraLaboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil.ORCID https://orcid.org/0000-0002-4470-8444
Sunniva SigurdardóttirDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.ORCID https://orcid.org/0009-0009-7617-6815
Per SunnerhagenDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.ORCID https://orcid.org/0000-0002-0967-8729
Izabela Marques Dourado BastosLaboratory of Pathogen-Host Interaction (LIPH), Institute of Biological Sciences, Universidade de Brasília, Brasília, Brazil.ORCID https://orcid.org/0000-0002-2785-4255
Richard GessnerHolistic Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch, South Africa.
Kelly ChibaleHolistic Drug Discovery and Development Center (H3D), University of Cape Town, Rondebosch, South Africa.ORCID https://orcid.org/0000-0002-1327-4727
Carolina Horta AndradeLaboratory of Molecular Modeling and Drug Design (LabMol), Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, Brazil.ORCID https://orcid.org/0000-0003-0101-1492

Funding

CAPES 001CNPq #440373/2022-0CNPq #444750/2024-0CNPq BRICS STI COVID-19 #441038/2020-4FAPEG #202010267000272South African Medical Research Council (SAMRC)STINT BR2018-8017Strategic Innovation Partnerships (SHIP) unit of the SAMRCSwedish Research Council 2020-05738Swedish Research Council 2021-03667the Technology Innovation Agency (TIA)
6 · The paper itself

Abstract

The SARS-CoV-2 3-chymotrypsin-like (3CL

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSARS-CoV-2COVID-19 Drug TreatmentDrug DiscoveryHumansLigandsMachine LearningMolecular Docking SimulationStructure-Activity Relationship3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesLigandsProtease Inhibitors3‐chymotrypsin‐like proteaseantiviral agentscomputational chemistryComputer‐Aided Drug Designdrug discoverymachine learningMpro

Identifiers

PMID41957532
PMCPMC13065885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.